15 results about "High intraocular pressure" patented technology

The invention belongs to the technical field of medicines, and discloses an application of a Necrosulfenamide (NSA) compound in preparation of a medicine for resisting glaucoma trabecular network fibrosis. The NSA can inhibit abnormal activation of necroptosis-related pathways and significantly down-regulate fibrosis key factors, so that the structure and function of trabecular meshwork tissues are improved, and the aqueous humor outflow capacity is recovered. It is found for the first time that NSA not only has a stable and lasting intraocular pressure lowering effect, but also can reduce retinal ganglion cell damage in an intraocular hypertension state, and has definite treatment and protection effects on non-acute glaucoma and intraocular hypertension. The regulation effect of NSA on trabecular meshwork fibrosis is not disclosed in the prior art, the research blank in the field is filled, and a new pharmacological target and a clinical application strategy are provided for prevention and treatment of glaucoma and related intraocular hypertension diseases.

The invention discloses a dual-channel drug delivery treatment system for open-angle glaucoma night intraocular hypertension, and relates to the technical field of medical instruments and clinical assistance. The system comprises a central control module, a time window control module, an intelligent double-medicine-bin medicine feeding module, a user interaction module, a data management and analysis module, a communication module, a safety and self-checking module and a power supply and management module. According to the invention, through the time window control module, the traditional morning administration is changed into night administration or individualized administration before intraocular pressure peak, the synchronization of the drug action peak and the night intraocular pressure peak is ensured, and through the intelligent double-drug-bin administration module and the precise metering pump, two drugs with the lowest effective dose are precisely delivered strictly according to the specific sequence of PGA first and CAI second; the time sequence control and precise quantitative administration based on the drug synergistic effect mechanism can ensure the synergistic antihypertensive curative effect, and can obviously avoid the high incidence rate adverse reaction caused by standard dosage combination.

Provided herein are compounds comprising a formula of 4-(3- amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-y I) benzyl adamantane carboxylate (e.g., compounds of formula (I) ) or a pharmaceutically acceptable salt thereof. The compounds are useful for reducing intraocular pressure and for treating glaucoma or ocular hypertension. Formula (I).

The application provides a use of a combination of metoclopramide and latanoprost for preparing an anticoagulant drug, and belongs to the technical field of biological medicines. It is accidentally found that the anticoagulant effect of patients with deep vein thrombosis combined with high intraocular pressure is improved after long-term continuous oral administration of metoclopramide. Thanks to this beneficial discovery, the application realizes good anticoagulant effect by applying the latanoprost liniment in a topical manner on the basis of oral administration of metoclopramide. The application is convenient to administer, has definite and sustained curative effect, and is safe and reliable. The application expands the optional range of anticoagulant drugs, and realizes better curative effect at the same time, and has outstanding technical advantages and wide popularization prospect.

The application provides a medical atomization eyeshade, which comprises an eye covering mechanism, a head fixing object and a heat alternating mechanism. The eye covering mechanism is used for covering the eyes of a patient. The head fixing object is arranged on the outer surface of the eye covering mechanism and is used for fixing and limiting the position of the eye covering mechanism in cooperation with the head of the patient. The heat alternating mechanism is arranged on the outer surface of the eye covering mechanism and is in communication with the inside of the eye covering mechanism. The medicine outside is introduced into the inside of the eye covering mechanism through the heat alternating mechanism and contacts the eyes of the patient. In use, the heat alternating mechanism intermittently heats and stops heating the atomized medicine according to the setting during the process that the atomized medicine is introduced into the inside of the eye covering mechanism through the heat alternating mechanism, so that the medicine generates cold-heat alternation, the circulation of the eyes is promoted through the cold-heat alternating medicine, and the symptoms of high intraocular pressure are reduced or alleviated.

The application belongs to the field of intraocular pressure measurement, and discloses a portable LC wireless intraocular pressure sensor signal acquisition device and application thereof. The device comprises: an intraocular pressure acquisition impedance module for continuously collecting intraocular pressure data signals and generating inductive coupling; a signal conditioning circuit for generating and transmitting amplified sweep signals of different frequencies to the intraocular pressure acquisition impedance module to cause inductive coupling of the intraocular pressure acquisition impedance module, so that the impedance of the intraocular pressure acquisition impedance module changes, and the amplitude ratio and phase difference of the intraocular pressure data signals collected after the impedance changes are detected and analog-to-digital converted; a control circuit for receiving the amplitude ratio and phase difference after analog-to-digital conversion, calculating the impedance real part value, and obtaining the impedance real part curve of the intraocular pressure acquisition impedance module and the resonant frequency at the peak value; and a power supply module for supplying power to the signal conditioning circuit and the control circuit. The application can improve the accuracy and convenience of intraocular pressure measurement.

The invention relates to the technical field of biology, in particular to a method for constructing an intraocular hypertension model through anterior chamber injection of GMA-EPL-LAP hydrogel. The construction method of the chronic intraocular hypertension animal model is high in stability and more suitable for long-term observation and research, the problem that the model is poor in stability is solved, the intraocular hypertension maintaining time is greatly prolonged, and the risk that intraocular pressure is increased due to repeated injection after the intraocular pressure is reduced is reduced; operation is easy and convenient, complex instruments and technologies are not needed, and harm to animals can be reduced; the application range is wide; and the hydrogel can be gradually degraded and absorbed in vivo, so that the potential safety hazard caused by long-term implantation of the hydrogel in vivo is avoided.

This invention relates to the field of biomedical technology, specifically proposing a method for preparing chiral cadmium selenide quantum dots and their application in retinal degeneration. By precisely controlling the reaction conditions, highly efficient chiral cadmium selenide quantum dots were successfully synthesized. The chiral cadmium selenide quantum dots of this invention exhibit significant protective effects against retinal damage caused by high intraocular pressure or oxidative stress, effectively improving the survival rate of retinal ganglion cells and alleviating retinal pathological changes. In a rat model, topical ocular administration demonstrated good therapeutic efficacy and biosafety. This invention provides new ideas and methods for the treatment of retinal degeneration and has broad clinical application prospects. Furthermore, the preparation method of these quantum dots and their complexes is simple and low-cost, providing new possibilities for expanding the application of quantum dots in the biomedical field.

The application provides an application of alpha-ketoglutaric acid in improving corneal endothelial injury and dysfunction, and belongs to the technical field of biological medicine. The application finds that, as a key metabolic intermediate in the tricarboxylic acid cycle, alpha-ketoglutaric acid can significantly reduce corneal endothelial cell injury and dysfunction induced by various causes such as high glucose, genetic defects, high intraocular pressure and surgical trauma by improving mitochondrial energy metabolism, reducing oxidative stress, stabilizing mitochondrial structure and membrane potential. Experiments prove that alpha-ketoglutaric acid can be used in the form of local administration such as eye drops, anterior chamber perfusion, systemic oral administration or combined administration, effectively reduces corneal edema, reduces central corneal thickness, shortens the recovery time of corneal transparency, and has a clear protection and repair effect on diabetic-related corneal endothelial lesions, Fuchs corneal endothelial dystrophy, glaucoma high intraocular pressure injury and intraocular surgery-related endothelial injury.

Provided herein are compounds comprising a formula of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl adamantane carboxylate (e.g., compounds of formula (I) or formula (II)) or a pharmaceutically acceptable salt thereof. The compounds are useful for reducing intraocular pressure and for treating glaucoma or ocular hypertension.

The application discloses a method for constructing a glaucoma intervention disease model, and relates to the field of glaucoma research. The MAdCAM of a non-human target mammal is not expressed or is inhibited, and thus the animal model constructed does not itself show glaucoma phenotypes such as damage or loss of ganglion cells. A new glaucoma animal model can be obtained by inducing high intraocular pressure of the animal. Compared with a wild-type high intraocular pressure model, the new glaucoma animal model has reduced damage of retinal ganglion cells, and the loss of ganglion cells in different regions of the retina is obviously reduced, the glaucoma symptoms are relieved, and the glaucoma course is delayed. It is indicated that the model can be used for related research on glaucoma diseases, and especially provides an animal model basis and research reference for research on the pathogenesis and intervention strategies of glaucoma. In addition, the glaucoma intervention animal model provided by the application can be used for research on retinal ganglion cell nerve damage.

A high intraocular pressure discrimination method based on eye video dynamic fusion double-branch complementary features belongs to the technical field of physiological signal detection, and the method comprises the following steps: firstly, collecting eye videos and synchronously acquiring intraocular pressure labels to construct a training data set; secondly, using a trained semantic segmentation model to respectively segment the iris-pupil region and the sclera region from the eye video frames, and extracting the RGB time sequence signals of each region; thirdly, further extracting the blood volume pulse (BVP) signals from the two RGB signals respectively, segmenting by using a sliding window and converting into a two-dimensional space-time feature map; and finally, constructing and training a high intraocular pressure discrimination model DB-CFFNet, which respectively inputs the two space-time feature maps, realizes the classification and discrimination of the intraocular pressure state through double-branch feature extraction and fusion. The method realizes low-cost and continuous dynamic intraocular pressure state monitoring based on a common camera.

Described herein are devices used to treat high intraocular pressure and glaucoma. An example device includes a plate comprising a first surface opposite a second surface. The first surface includes a series of fluid channels. The device also includes a first coating on the first surface and a second coating on the second surface. The device is configured to lower intraocular pressure by draining aqueous humor from an anterior chamber to subconjunctival space of a patient's eye.

Described herein are insertion tools for inserting a treatment device into a pocket formed between conjunctival tissue and scleral tissue for treating high intraocular pressure and glaucoma. An insertion tool (800) includes a scissoring mechanism or an expandable mechanism that is configured to expand a pocket formed between conjunctival tissue and scleral tissue. The scissoring mechanism or the expandable mechanism is also configured to unfurl a treatment device within the pocket.

The present disclosure provides ophthalmic dual and triple compound medicine compositions for treating glaucoma and ocular hypertension. Through a salt modification technology, stability of the medicine compositions is improved remarkably. The dual compound medicine composition is prepared from netarsudil free alkali or pharmaceutically acceptable salts of the same and a β-adrenergic receptor blocker. The triple compound medicine composition is prepared from the netarsudil free alkali or the pharmaceutically acceptable salts of the same, the β-adrenergic receptor blocker and a prostaglandin analog. The dual and triple compound medicine compositions have excellent stability when pH is in a range from 4.5 to 5.4, an effective dose of the medicine composition of the present disclosure is applied to eyes of a patient in need once a day at bedtime or close to bedtime, an intra-ocular pressure can be reduced efficiently and quickly, the intra-ocular pressure remains in a physiological range for a longer time, side effects are minor, and patient compliance is high.